Association of cannabis abuse/dependence on risks of erectile dysfunction and testosterone deficiency using a large claims database analysis.

IF 3.3 3区 医学 Q1 UROLOGY & NEPHROLOGY
Ryan Davis, Jacob Hershenhouse, Marissa Maas, Jeffrey Loh-Doyle, Kian Asanad
{"title":"Association of cannabis abuse/dependence on risks of erectile dysfunction and testosterone deficiency using a large claims database analysis.","authors":"Ryan Davis, Jacob Hershenhouse, Marissa Maas, Jeffrey Loh-Doyle, Kian Asanad","doi":"10.1093/jsxmed/qdaf043","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cannabis is widely consumed across the United States; however, studies assessing the association between cannabis use and male sexual health, specifically erectile dysfunction (ED) and testosterone deficiency (TD), have mixed results and small sample sizes.</p><p><strong>Aim: </strong>To evaluate the impact of cannabis abuse/dependence on risks of ED, phosphodiesterase-5 inhibitor (PDE5-i) prescription, TD, and testosterone replacement therapy (TRT) using a population-level analysis.</p><p><strong>Methods: </strong>We sampled men ≥18 years old from the large claims database, TriNetX, in 2025. Patients previously diagnosed with or treated for ED or TD and those with prior prostatectomy were excluded. Patients were split into two cohorts: diagnoses of cannabis abuse/dependence or not. Cohorts were propensity score-matched on 49 pertinent factors. Risk of ED, TD, PDE5-i prescription, and TRT were compared at 3 months-1 year (patients from 2005-2024) and 3-5 years (patients from 2005-2020) from cannabis diagnoses. Subgroups of age younger or older than 40 years were also analyzed. Kaplan-Meier survival analysis was performed to assess differences in time to development of ED and TD.</p><p><strong>Outcomes: </strong>Primary outcomes were risk of diagnosis of ED or TD (testosterone level <300 ng/dL). Secondary outcomes were risk of new prescription of PDE5-i or TRT.</p><p><strong>Results: </strong>Between 2005-2024, 30 964 patients with and 1 473 182 without cannabis diagnoses were identified with 29 442 in each cohort after matching. Between 2005-2020, 17 948 patients with and 839 496 without cannabis abuse/dependence were identified, with 17 211 in each cohort after matching. Cannabis abuse/dependence was significantly associated with ED (0.9% vs. 0.2%, RR = 3.99 [3.05, 5.21]), TD (0.2% vs. 0.1%, RR = 2.19 [1.45, 3.31]), and PDE5-i prescription (0.8% vs. 0.2%, RR = 3.80 [2.86, 5.04]) at 3 months-1 year, and only ED at 3-5 years (1.61% vs. 1.34%, RR = 1.20, 95% CI = [1.01, 1.43]). Kaplan-Meier analysis revealed significantly shorter time to development of ED (HR = 1.65, 95% CI = [1.47, 1.85]) and TD (HR = 1.34, 95% CI = 1.07, 1.69]) associated with cannabis abuse/dependence. No association between cannabis abuse/dependence and TRT was found. In those <40 years old, only ED and PDE5-i were significant at 3 months-1 year, but not at 3-5 years.</p><p><strong>Clinical implications: </strong>Our findings support an association between cannabis abuse/dependence, ED, and TD, which providers may consider when treating patients with these diagnoses.</p><p><strong>Strengths and limitations: </strong>Strengths include having a large, national sample of patients. Limitations include inability to assess dose-dependent relationships and using diagnosis codes as proxies for cannabis use.</p><p><strong>Conclusion: </strong>Cannabis abuse/dependence is associated with increased risk of ED, PDE5-i prescription, and TD.</p>","PeriodicalId":51100,"journal":{"name":"Journal of Sexual Medicine","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Sexual Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jsxmed/qdaf043","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Cannabis is widely consumed across the United States; however, studies assessing the association between cannabis use and male sexual health, specifically erectile dysfunction (ED) and testosterone deficiency (TD), have mixed results and small sample sizes.

Aim: To evaluate the impact of cannabis abuse/dependence on risks of ED, phosphodiesterase-5 inhibitor (PDE5-i) prescription, TD, and testosterone replacement therapy (TRT) using a population-level analysis.

Methods: We sampled men ≥18 years old from the large claims database, TriNetX, in 2025. Patients previously diagnosed with or treated for ED or TD and those with prior prostatectomy were excluded. Patients were split into two cohorts: diagnoses of cannabis abuse/dependence or not. Cohorts were propensity score-matched on 49 pertinent factors. Risk of ED, TD, PDE5-i prescription, and TRT were compared at 3 months-1 year (patients from 2005-2024) and 3-5 years (patients from 2005-2020) from cannabis diagnoses. Subgroups of age younger or older than 40 years were also analyzed. Kaplan-Meier survival analysis was performed to assess differences in time to development of ED and TD.

Outcomes: Primary outcomes were risk of diagnosis of ED or TD (testosterone level <300 ng/dL). Secondary outcomes were risk of new prescription of PDE5-i or TRT.

Results: Between 2005-2024, 30 964 patients with and 1 473 182 without cannabis diagnoses were identified with 29 442 in each cohort after matching. Between 2005-2020, 17 948 patients with and 839 496 without cannabis abuse/dependence were identified, with 17 211 in each cohort after matching. Cannabis abuse/dependence was significantly associated with ED (0.9% vs. 0.2%, RR = 3.99 [3.05, 5.21]), TD (0.2% vs. 0.1%, RR = 2.19 [1.45, 3.31]), and PDE5-i prescription (0.8% vs. 0.2%, RR = 3.80 [2.86, 5.04]) at 3 months-1 year, and only ED at 3-5 years (1.61% vs. 1.34%, RR = 1.20, 95% CI = [1.01, 1.43]). Kaplan-Meier analysis revealed significantly shorter time to development of ED (HR = 1.65, 95% CI = [1.47, 1.85]) and TD (HR = 1.34, 95% CI = 1.07, 1.69]) associated with cannabis abuse/dependence. No association between cannabis abuse/dependence and TRT was found. In those <40 years old, only ED and PDE5-i were significant at 3 months-1 year, but not at 3-5 years.

Clinical implications: Our findings support an association between cannabis abuse/dependence, ED, and TD, which providers may consider when treating patients with these diagnoses.

Strengths and limitations: Strengths include having a large, national sample of patients. Limitations include inability to assess dose-dependent relationships and using diagnosis codes as proxies for cannabis use.

Conclusion: Cannabis abuse/dependence is associated with increased risk of ED, PDE5-i prescription, and TD.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Sexual Medicine
Journal of Sexual Medicine 医学-泌尿学与肾脏学
CiteScore
6.20
自引率
5.70%
发文量
826
审稿时长
2-4 weeks
期刊介绍: The Journal of Sexual Medicine publishes multidisciplinary basic science and clinical research to define and understand the scientific basis of male, female, and couples sexual function and dysfunction. As an official journal of the International Society for Sexual Medicine and the International Society for the Study of Women''s Sexual Health, it provides healthcare professionals in sexual medicine with essential educational content and promotes the exchange of scientific information generated from experimental and clinical research. The Journal of Sexual Medicine includes basic science and clinical research studies in the psychologic and biologic aspects of male, female, and couples sexual function and dysfunction, and highlights new observations and research, results with innovative treatments and all other topics relevant to clinical sexual medicine. The objective of The Journal of Sexual Medicine is to serve as an interdisciplinary forum to integrate the exchange among disciplines concerned with the whole field of human sexuality. The journal accomplishes this objective by publishing original articles, as well as other scientific and educational documents that support the mission of the International Society for Sexual Medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信